Publications by authors named "Peter Hunyady"

Background: Secondary sclerosing cholangitis (SSC) is a rare disease with poor prognosis. Cases of SSC have been reported following coronavirus disease 2019 (COVID-SSC). The aim of this study was to compare COVID-SSC to SSC in critically ill patients (SSC-CIP) and to assess factors influencing transplant-free survival.

View Article and Find Full Text PDF
Article Synopsis
  • The study assessed the effectiveness of liver biopsy in diagnosing patients with acute liver injury or failure over a ten-year period at a German hospital.
  • Out of 66 patients, only a few experienced complications, while biopsy results clarified the cause of liver issues in several cases, especially with drug-induced injuries.
  • The findings suggest that while liver biopsy is crucial for excluding extrahepatic diseases, blood tests for immunoglobulins and autoantibodies are more useful for differentiating between autoimmune hepatitis and drug-induced liver injury.
View Article and Find Full Text PDF

Background: Before performing endoscopy to remove prophylactic pancreatic stents placed in patients with high risk of post-endoscopic retrograde cholangiopancreatography pancreatitis (PEP), X-ray imaging is recommended to confirm the stents position in the pancreatic duct.

Objectives: The aim of the present study was to investigate the feasibility of prophylactic pancreatic stent detection by transabdominal ultrasonography, to reduce the burden of X-ray imaging, which is currently the golden standard.

Methods: All patients who received a pancreatic stent for PEP prophylaxis were included in the present prospective trial.

View Article and Find Full Text PDF

Patients with acute myeloid leukemia (AML) are often exposed to broad-spectrum antibiotics and thus at high risk of Clostridioides difficile infections (CDI). As bacterial infections are a common cause for treatment-related mortality in these patients, we conducted a retrospective study to analyze the incidence of CDI and to evaluate risk factors for CDI in a large uniformly treated AML cohort. A total of 415 AML patients undergoing intensive induction chemotherapy between 2007 and 2019 were included in this retrospective analysis.

View Article and Find Full Text PDF